7/1015 sources · 14 publishersUpdated Oct 19, 21:37 UTC
FDA clears Ryzumvi for adult presbyopia
On October 16, 2026, the U.S. FDA authorized RYZUMVI, a 0.75% phentolamine eye solution, for presbyopia in adults. The decision expands Viatris' U.S. use of the drug beyond pharmacologically induced mydriasis. Viatris holds U.S. commercialization rights through its arrangement with Opus Genetics and is looking for a U.S. partner for the new indication.
Why it matters
The ruling gives Viatris an additional approved use and a potential ophthalmology revenue opportunity. Viatris says it is exploring a U.S. commercialization partner, so the launch approach for this indication has not been finalized.
Key facts
- 1The U.S. FDA expanded RYZUMVI's approved uses on October 16, 2026, to include adult presbyopia. prnewswire.com
- 2Viatris has exclusive U.S. commercialization rights under its global licensing arrangement with Opus Genetics. prnewswire.com
- 3In the VEGA-3 Phase 3 trial, 27.2% of patients receiving phentolamine met the primary endpoint, compared with 11.5% receiving placebo. optometrytimes.com
- 4For the presbyopia indication, the most frequently reported ocular adverse reactions were conjunctival hyperemia at 21% and instillation-site irritation at 16%. prnewswire.com
Open questions
- Material 10 describes Ryzumvi as the only FDA-authorized presbyopia treatment, while material 1 says LENZ Therapeutics has an approved presbyopia treatment; the materials do not reconcile those claims.
- Material 1 reports that the approval triggered a milestone payment, but the amount and terms are not provided or confirmed in the primary announcement.
Summary written by AlphAI AI Desk from 15 of 15 sources. Not investment advice. Figures are as stated by the linked sources.